Nick Teoh

563 total citations
20 papers, 447 citations indexed

About

Nick Teoh is a scholar working on Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Nick Teoh has authored 20 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Radiology, Nuclear Medicine and Imaging, 12 papers in Pathology and Forensic Medicine and 8 papers in Oncology. Recurrent topics in Nick Teoh's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Lymphoma Diagnosis and Treatment (12 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Nick Teoh is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Lymphoma Diagnosis and Treatment (12 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Nick Teoh collaborates with scholars based in United States, France and Germany. Nick Teoh's co-authors include David M. Goldenberg, William A. Wegener, Thomas Dörner, Gerd R Burmester, John P. Leonard, Morton Coleman, Stephen J. Schuster, Félix Couture, Christos Emmanouilides and Heather Horne and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Nick Teoh

20 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nick Teoh United States	9	258	217	164	147	118	20	447
L Nogueira France	9	255 1.0×	130 0.6×	373 2.3×	43 0.3×	37 0.3×	19	498
Laura J. Gibbons United Kingdom	10	79 0.3×	204 0.9×	283 1.7×	47 0.3×	96 0.8×	10	492
Trieneke C. G. Timmer Netherlands	6	70 0.3×	174 0.8×	254 1.5×	74 0.5×	31 0.3×	8	442
Rita I. Jain United States	9	128 0.5×	182 0.8×	140 0.9×	23 0.2×	36 0.3×	10	428
A. Godwood United Kingdom	11	94 0.4×	265 1.2×	251 1.5×	24 0.2×	63 0.5×	30	603
Carelle C. Reparon‐Schuijt Netherlands	7	165 0.6×	131 0.6×	206 1.3×	21 0.1×	25 0.2×	9	337
Vladimir M. Liarski United States	10	57 0.2×	403 1.9×	248 1.5×	39 0.3×	17 0.1×	18	572
Aderajew Waka Germany	5	105 0.4×	197 0.9×	200 1.2×	26 0.2×	46 0.4×	6	359
Marianne Wolfson‐Reichlin United States	9	282 1.1×	343 1.6×	393 2.4×	46 0.3×	14 0.1×	10	555
Peter Sahlström Sweden	9	90 0.3×	199 0.9×	148 0.9×	17 0.1×	17 0.1×	12	334

Countries citing papers authored by Nick Teoh

Since Specialization

Citations

This map shows the geographic impact of Nick Teoh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick Teoh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick Teoh more than expected).

Fields of papers citing papers by Nick Teoh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nick Teoh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick Teoh. The network helps show where Nick Teoh may publish in the future.

Co-authorship network of co-authors of Nick Teoh

This figure shows the co-authorship network connecting the top 25 collaborators of Nick Teoh. A scholar is included among the top collaborators of Nick Teoh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nick Teoh. Nick Teoh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldsmith, Stanley J., Michael Holt, Aldo N. Serafini, et al.. (2011). Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC). 52. 357–357. 1 indexed citations

Ocean, Allyson J., Kenneth Pennington, Alberto J. Montero, et al.. (2011). Activity of fractionated radioimmunotherapy with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC).. Journal of Clinical Oncology. 29(4_suppl). 240–240. 5 indexed citations

Allen, Steven L., R. Kanti, Rebecca Elstrom, et al.. (2009). Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies.. Blood. 114(22). 3757–3757. 9 indexed citations

Saleh, Mansoor N., Howard A. Liebman, Zale P. Bernstein, et al.. (2009). Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).. Blood. 114(22). 1322–1322. 4 indexed citations

Kaufman, Jonathan L., Rubén Niesvizky, Edward A. Stadtmauer, et al.. (2009). Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma. Journal of Clinical Oncology. 27(15_suppl). 8593–8593. 18 indexed citations

Allen, Steven L., K. R., Rebecca Elstrom, et al.. (2009). Subcutaneous injections of low doses of veltuzumab (humanized anti-CD20 antibody): Objective responses in B-cell malignancies. Journal of Clinical Oncology. 27(15_suppl). 8530–8530. 5 indexed citations

Leonard, John P., Stephen J. Schuster, Christos Emmanouilides, et al.. (2008). Durable complete responses from therapy with combined epratuzumab and rituximab. Cancer. 113(10). 2714–2723. 81 indexed citations

Goldenberg, D M, Edmund A. Rossi, Thomas M. Cardillo, et al.. (2008). Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab. Journal of Clinical Oncology. 26(15_suppl). 3043–3043. 2 indexed citations

Kaufman, Jonathan L., Rubén Niesvizky, Edward A. Stadtmauer, et al.. (2008). First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma. Blood. 112(11). 3697–3697. 10 indexed citations

10.

Liebman, Howard A., Mansoor N. Saleh, Thomas M. Cosgriff, et al.. (2008). Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study.. Blood. 112(11). 3412–3412. 1 indexed citations

11.

Dörner, Thomas, et al.. (2008). Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Research & Therapy. 10(5). 406–406. 3 indexed citations

12.

Leonard, John P., Stephen J. Schuster, Christos Emmanouilides, et al.. (2007). Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin’s Lymphoma (NHL).. Blood. 110(11). 3419–3419. 1 indexed citations

13.

Güleç, Seza A., Steven J. Cohen, Lionel S. Zuckier, et al.. (2007). First clinical experience with ⁹⁰Y-radiolabeled humanized anti-MUC1 antibody (hPAM4) in patients with advanced pancreatic cancer: A phase I study. Journal of Clinical Oncology. 25(18_suppl). 15034–15034. 3 indexed citations

14.

Morschhauser, Franck, John P. Leonard, Luis Fayad, et al.. (2007). Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results. Journal of Clinical Oncology. 25(18_suppl). 8032–8032. 9 indexed citations

15.

Morschhauser, Franck, John P. Leonard, Luis Fayad, et al.. (2006). Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results.. Blood. 108(11). 2719–2719. 6 indexed citations

16.

Dörner, Thomas, et al.. (2006). Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Research & Therapy. 8(3). R74–R74. 241 indexed citations

17.

Leonard, John P., Bertrand Coiffier, Marie‐Odile Petillon, et al.. (2006). Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL. Journal of Clinical Oncology. 24(18_suppl). 7530–7530. 12 indexed citations

18.

Strauss, Sandra J., Franck Morschhauser, Martin Gramatzki, et al.. (2005). The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.. Blood. 106(11). 4796–4796. 3 indexed citations

19.

Morschhauser, Franck, John P. Leonard, Bertrand Coiffier, et al.. (2005). Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma.. Blood. 106(11). 2428–2428. 22 indexed citations

20.

Dudewicz, Edward J., et al.. (1995). Entropy-Based Random Number Evaluation. American Journal of Mathematical and Management Sciences. 15(1-2). 115–153. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact